Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America
- PMID: 21755809
- DOI: 10.1055/s-0031-1296198
Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America
Abstract
Spontaneously-reported rates of adverse events (AEs) of intravenous (i.v.) iron products have not been compared since 2007. AEs in Europe (Eur) and North America (NA) have never been compared. New products have been marketed and many changes in prescribing habits have occurred since then, and the effect on AEs reporting is unclear. It was hypothesized that changing practices for i.v. iron products has caused changes in the rates of serious AEs and large differences exist between Eur and NA. Rates of AEs for three i.v. iron preparations (iron sucrose [IS], ferric gluconate [FG] and high and low MW iron dextran [HMWID, LMWID]) were compared by product and continent from January 1, 2003 to June 30, 2009 for selected countries in Eur and NA, using the Uppsala Monitoring Center's database. Rates of total, anaphylaxis and other serious allergic AEs were calculated as number of AEs divided by i.v. iron sales standardized to 100 mg dose equivalents (DEq) of iron. Quarterly sales (millions of 100 mg DEq of iron) increased from the first quarter 2003 to the end of the second quarter of 2009 by 1% for FG, 16% for IS and 2% for ID. Total AEs for NA plus Eur were similar for FG and IS, but total AEs were 6- to 7-fold higher for ID. Rates of anaphylaxis were 6- to 11-fold higher in Eur plus NA combined for ID than for IS or FG. In NA, there were substantially higher reports for total, anaphylaxis and other serious allergic AEs with FG compared to IS, whereas the reverse was the case in Eur. Odds ratios (OR) showed higher risks of anaphylaxis with FG in NA vs. Eur (OR = 4.40, P < 0.0001) and lower risks with IS (OR = 0.24, P < 0.0001). Odds of anaphylaxis with LMWID in Eur vs. FG and IS were 42.08 and 16.92 (both P < 0.0001), respectively. In NA, odds of anaphylaxis with ID vs. FG and IS were 2.36 and 17.73 (both P < 0.0001), respectively. Differences between NA and Eur may be related to varied treatment practices. ID had the highest rates of all types of AEs, and IS and FG had a continued trend for lowest rates of AEs.
Similar articles
-
Differences in the reporting rates of serious allergic adverse events from intravenous iron by country and population.Clin Adv Hematol Oncol. 2012 Feb;10(2):101-8. Clin Adv Hematol Oncol. 2012. PMID: 22402351
-
Hypersensitivity reactions and deaths associated with intravenous iron preparations.Nephrol Dial Transplant. 2005 Jul;20(7):1443-9. doi: 10.1093/ndt/gfh820. Epub 2005 Apr 26. Nephrol Dial Transplant. 2005. PMID: 15855210
-
Comparison of rates of reported adverse events associated with i.v. iron products in the United States.Am J Health Syst Pharm. 2012 Feb 15;69(4):310-20. doi: 10.2146/ajhp110262. Am J Health Syst Pharm. 2012. PMID: 22302256
-
Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.Am J Kidney Dis. 1999 Mar;33(3):464-70. doi: 10.1016/s0272-6386(99)70183-6. Am J Kidney Dis. 1999. PMID: 10070910 Review.
-
Parenteral iron therapy options.Am J Hematol. 2004 May;76(1):74-8. doi: 10.1002/ajh.20056. Am J Hematol. 2004. PMID: 15114602 Review.
Cited by
-
Authors' reply to Schaffalitzky de Muckadell and colleague's Comment on "Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017".Drug Saf. 2019 May;42(5):693-696. doi: 10.1007/s40264-019-00815-4. Drug Saf. 2019. PMID: 30937851 Free PMC article. No abstract available.
-
Double bull's eye for post-operative intravenous iron in patient blood management: better outcome and cost-effective.Blood Transfus. 2014 Jan;12(1):7-9. doi: 10.2450/2013.0227-13. Epub 2013 Dec 4. Blood Transfus. 2014. PMID: 24333091 Free PMC article. No abstract available.
-
Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake.Nanomaterials (Basel). 2017 Dec 15;7(12):451. doi: 10.3390/nano7120451. Nanomaterials (Basel). 2017. PMID: 29244729 Free PMC article.
-
IV iron formulations and use in adults.Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):622-629. doi: 10.1182/hematology.2023000495. Hematology Am Soc Hematol Educ Program. 2023. PMID: 38066930 Free PMC article.
-
Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.Inflamm Allergy Drug Targets. 2012 Feb;11(1):66-78. doi: 10.2174/187152812798889358. Inflamm Allergy Drug Targets. 2012. PMID: 22309085 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical